Back to top
more

Dynavax Technologies (DVAX)

(Real Time Quote from BATS)

$11.06 USD

11.06
1,115,569

-0.13 (-1.16%)

Updated Sep 11, 2024 03:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Makes Dynavax Technologies (DVAX) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Dynavax Technologies (DVAX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zoetis' (ZTS) Companion Animal Products to Boost Revenues

by Zacks Equity Research

Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.

Bristol Myers' (BMY) Opdivo Gets EC Nod for Label Expansion

by Zacks Equity Research

Bristol Myers (BMY) obtains approval in the EU for Opdivo for the adjuvant treatment of adults and adolescents with stage IIB or IIC melanoma who have undergone complete resection.

Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher

by Zacks Equity Research

Krystal (KRYS) announces the sale of its priority review voucher for a consideration of $100 million. The stock of the company rises 5.2% on the news.

Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold

by Zacks Equity Research

Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.

Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why

by Zacks Equity Research

Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.

Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why

by Zacks Equity Research

Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.

Novartis (NVS) Plans to Spin-Off Sandoz in Early October

by Zacks Equity Research

Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.

Regeneron's (REGN) Application for Blood Cancer Drug Accepted

by Zacks Equity Research

Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.

Bristol Myers (BMY) Announces Positive Updated NSCLC Data

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer.

Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies

by Zacks Equity Research

Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.

Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View

by Zacks Equity Research

Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.

Wall Street Analysts See a 70.61% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 70.6% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss

by Zacks Equity Research

FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.

bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues

by Zacks Equity Research

bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows

by Zacks Equity Research

Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.

Bausch Health's (BHC) Q2 Earnings & Sales Beat, '23 View Raised

by Zacks Equity Research

Bausch's (BHC) second-quarter earnings and sales surpass estimates. The company increases its revenue guidance for 2023.

Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology

by Zacks Equity Research

Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.

Best Momentum Stocks to Buy for August 4th

by Zacks Equity Research

IAS, DVAS and KTOS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 4, 2023.

New Strong Buy Stocks for August 4th

by Zacks Equity Research

CVI, JJSF, IAS, DVAX and EB have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2023.

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 133.33% and 18.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.

BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo.

Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.

Swedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 27.27% and 16.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?